AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 173 min read$MDT

Medtronic (MDT) Raises its Outlook Again as Heart Device Demand Keeps Climbing

Medtronic (MDT) raised its fiscal 2027 profit forecast to $5.94-$6.00 per share and increased revenue growth outlook to 7.25%-7.75%. Q1 revenue was $9.756B, up 13.7%, with all segments showing double-digit growth. The company faces tariff headwinds and potential diabetes business separation.

Original reporting
yahoo.com
Published Sep 17, 2026, 3:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 3:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medtronic (MDT) Raises its Outlook Again as Heart Device Demand Keeps Climbing — source image
Source · yahoo.com
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

The guidance lift is likely to attract buying interest, but tariff costs and the pending diabetes business separation add risk.

02

Market read

First‑report earnings guidance upgrade for a large med‑device firm; material for traders.

03

What to watch

Potential competitive pressure from Abbott, Dexcom, and J&J may limit market‑share gains.

Relevance 7/10Novelty 7/10Timing: post‑earnings

Background

Medtronic reported FY2027 Q1 results with revenue up 13.7% YoY and EPS beat, then raised its FY2027 guidance.

Company-level read

Ticker impact

$MDTBullishHigh confidence
Context

Medtronic raised the lower end of its FY2027 EPS guidance to $5.94 and lifted organic revenue growth outlook to 7.25%-7.75% after reporting a 13.7% revenue beat.

Expected impact

Potential upside of 3-5% in the near term as investors price in higher earnings.

Evidence & confidence

The guidance raise is material, includes higher EPS range and revenue growth, and follows a strong quarterly beat.

Market effects

Sector

Boosts outlook for the broader medical‑device sector, especially cardiovascular and diabetes segments.

Regional

Positive for U.S. healthcare stocks and may lift European med‑tech peers.

Global

Reinforces demand trends for heart devices worldwide.

Counterpoint

What could challenge this read

Tariff headwinds and uncertainty around the diabetes spin‑off could pressure margins, suggesting caution.

Key entities

  • company
    Medtronic plc

    Medical‑device maker raising FY2027 guidance.

  • partner
    Cornerstone Robotics

    Partnered with Medtronic for the Sentire surgical robot.

Read at source← All news

Related articles

SEP 18
$MDTMedAI 8/10

Two Catalysts for Medtronic: Surgical Robots and Dividend King Run

Medtronic (MDT) shares have fallen 3% YTD but attract investors due to Hugo robotic surgery system growth and dividend increases. Hugo gained FDA clearance for urology and filed for broader use. Q1 FY2027 revenue rose 13.7% to $9.8B, EPS up 40.7% to $1.14. Guidance raised: organic revenue growth now 7.25-7.75%, GAAP EPS $5.94-$6.00. Dividend raised 1.4% to $0.72, nearing 'Dividend King' status. Trades at 22x trailing earnings, 15x forward earnings.

nai500.com3 min
SEP 17
$MDTHighAI 8/10

Medtronic Advances Diabetes Spin

Medtronic (MDT) launched an exchange offer for up to 225,361,295 MiniMed Group Inc. shares, part of its diabetes business separation. It corrected a prospectus error regarding the guaranteed delivery period for tender documentation, which now expires at 5:00 p.m. NY time on the second NYSE trading day after execution.

tipranks.com1 min
SEP 17
$MDTHighAI 9/10

[SC TO-I/A] Medtronic plc Amended Issuer Tender Offer

Medtronic plc amended its tender offer to exchange up to 225,361,295 shares of MiniMed Group, Inc. common stock for its own shares, with a potential increase of 27,452,053 shares if oversubscribed. The offer, filed with the SEC, aims to exchange approximately 80.1% of MiniMed's outstanding shares. MiniMed has also filed a registration statement for the new shares.

stocktitan.net2 min
SEP 17
$MDTMed

Medtronic plc (MDT): Other Events

Medtronic plc (MDT) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events On September 14, 2026, Medtronic plc, a public limited company organized under the laws of Ireland (“Medtronic”), commenced an offer to exchange (the “Exchange Offer”) up to 225,361,295 newly issued shares of common stock, par value $0.01 per share (“MiniM

SEC EDGAR 8-K2 min
SEP 17
$MDTHighAI 8/10

Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?

Medtronic (MDT) shares are down 3% this year, but the company's Hugo robotic-assisted surgery system is gaining market share. The FDA approved Hugo for urological procedures, and Medtronic submitted new filings for broader use. Q1 2027 revenue was $9.8B, up 13.7% YoY, with EPS of $1.14, up 40.7%. The company raised full-year guidance and is on track to become a Dividend King. Medtronic's dividend yield is 3.06%, and it is expanding in cardiac and spinal technologies.

fool.com3 min
SEP 17
$MDTMed

Medtronic Sees AI, Ablation and Targeted M&A Fueling Growth

Medtronic (MDT) reported Q1 growth of 7% (excluding an extra week), driven by innovations in cardiac ablation, renal denervation, robotics, and pelvic health. Cardiac ablation revenue surpassed $2B, while pelvic health revenue grew 15%. The company is investing in robotics, structural heart, and neuroscience, and plans to focus on tuck-in acquisitions. Medtronic expects to discuss its growth outlook further at an upcoming Investor Day.

yahoo.com3 min